23 results on '"Yoffe L"'
Search Results
2. RNA SEQUENCING REVEALS DIFFERENT GENE EXPRESSION IN MALE VERSUS FEMALE DIFFUSE LARGE B‐CELL LYMPHOMA
- Author
-
Ghione, P, primary, Cortes Gomez, E, additional, Torka, P, additional, Sundaram, S, additional, Mavis, C, additional, Tabbo', F, additional, Gu, J, additional, Cacciapuoti, M. T, additional, Yoffe, L, additional, Wang, J, additional, Hernandez‐Ilizaliturri, F, additional, and Inghirami, G, additional
- Published
- 2021
- Full Text
- View/download PDF
3. Effective treatment of severe pseudo-autoimmune haemolytic anaemia after allogeneic haematopoietic stem cell transplantation using plasmapheresis-rituximab-ATG-cyclophosphamide containing protocol
- Author
-
Resnick, I. B., Shapira, M. Y., Gesundheit, B., Bitan, M., Rund, D., Zilberman, I., Miron, S., Yoffe, L., Lvovitch, A., Zelig, O., Manny, N., Or, R., and Slavin, S.
- Published
- 2007
4. Diversity and education in languages: the European situation
- Author
-
Broeder, P., van Wijk, C., Jimbo, H., Hisamura, K., Oda, M., Usui, Y., Yoffe, L., Language, Communication and Cognition, and Language and Globalization
- Published
- 2012
5. Professional roles and competence domains of the teacher
- Author
-
Broeder, P., Stokmans, M.J.W., Jimbo, H., Hisamura, K., Oda, M., Usui, Y., Yoffe, L., and Language and Globalization
- Published
- 2012
6. P085 Treatment of steroid refractory graft vs. host disease by intra-arterial infusion
- Author
-
Shapira, M.Y., primary, Bloom, A.I., additional, Or, R., additional, Resnick, I.B., additional, Aker, M., additional, Bitan, M., additional, Zilberman, I., additional, Miron, S., additional, Yoffe, L., additional, Levovic, A., additional, Slavin, S., additional, and Verstandig, A., additional
- Published
- 2007
- Full Text
- View/download PDF
7. Skyline impressions.
- Author
-
Yoffe, L.
- Subjects
- *
ART education - Abstract
Details the author's art project, in which her class painted the New York City skyline in the style of Impressionism. A discussion of Impressionism and the life of Claude Monet to inspire her class; How the project helped students understand the basics of Impressionist paintings; More.
- Published
- 1992
8. Primary origami.
- Author
-
Yoffe, L.
- Subjects
- *
ORIGAMI , *EDUCATION - Abstract
Presents origami, the ancient Japanese art of paper folding, as a valuable tool in art lessons to younger children. Kindergartners first taste with the cup, the bird and the bunny; First and second graders experience with the simple modular cube; Creation of forms from paper without glue or scissors; Importance of paper; Precise directions develop listening skills; Disappearance of behavior problems; Development of motor skills; Possibilities of origami; Details.
- Published
- 1991
9. Endothelial-leukemia interactions remodel drug responses uncovering T-ALL vulnerabilities
- Author
-
Luca Vincenzo Cappelli, Danilo Fiore, Jude M. Phillip, Liron Yoffe, Filomena Di Giacomo, William Chiu, Yang Hu, Clarisse Kayembe, Michael Ginsberg, Lorena Consolino, Jose Gabriel Barcia Duran, Nahuel Zamponi, Ari M. Melnick, Francesco Boccalatte, Wayne Tam, Olivier Elemento, Sabina Chiaretti, Anna Guarini, Robin Foà, Leandro Cerchietti, Shahin Rafii, Giorgio Inghirami, Cappelli, L. V., Fiore, D., Phillip, J. M., Yoffe, L., Di Giacomo, F., Chiu, W., Hu, Y., Kayembe, C., Ginsberg, M., Consolino, L., Barcia Duran, J. G., Zamponi, N., Melnick, A. M., Boccalatte, F., Tam, W., Elemento, O., Chiaretti, S., Guarini, A., Foa, R., Cerchietti, L., Rafii, S., and Inghirami, G.
- Subjects
Immunology ,Cell Biology ,Hematology ,Biochemistry - Abstract
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive and often incurable disease. To uncover therapeutic vulnerabilities, we first developed T-ALL patient–derived tumor xenografts (PDXs) and exposed PDX cells to a library of 433 clinical-stage compounds in vitro. We identified 39 broadly active drugs with antileukemia activity. Because endothelial cells (ECs) can alter drug responses in T-ALL, we developed an EC/T-ALL coculture system. We found that ECs provide protumorigenic signals and mitigate drug responses in T-ALL PDXs. Whereas ECs broadly rescued several compounds in most models, for some drugs the rescue was restricted to individual PDXs, suggesting unique crosstalk interactions and/or intrinsic tumor features. Mechanistically, cocultured T-ALL cells and ECs underwent bidirectional transcriptomic changes at the single-cell level, highlighting distinct “education signatures.” These changes were linked to bidirectional regulation of multiple pathways in T-ALL cells as well as in ECs. Remarkably, in vitro EC-educated T-ALL cells transcriptionally mirrored ex vivo splenic T-ALL at single-cell resolution. Last, 5 effective drugs from the 2 drug screenings were tested in vivo and shown to effectively delay tumor growth and dissemination thus prolonging overall survival. In sum, we developed a T-ALL/EC platform that elucidated leukemia-microenvironment interactions and identified effective compounds and therapeutic vulnerabilities.
- Published
- 2022
10. A Novel JAK1 Mutant Breast Implant-Associated Anaplastic Large Cell Lymphoma Patient-Derived Xenograft Fostering Pre-Clinical Discoveries
- Author
-
Robin Foà, Ahmet Dogan, Luca Vincenzo Cappelli, Steven M. Horwitz, Joseph Casano, Jude M Phillips, Paul Zumbo, Danilo Fiore, Liron Yoffe, David M. Weinstock, Leandro Cerchietti, Clarisse Kayembe, Federica Di Maggio, Elisa de Stanchina, Paola Ghione, Raul Rabadan, Zhaoqi Liu, Giorgio Inghirami, Wayne Tam, Inna Khodos, Shuhua Cheng, Doron Betel, Fiore, D., Cappelli, L. V., Zumbo, P., Phillips, J. M., Liu, Z., Cheng, S., Yoffe, L., Ghione, P., Di Maggio, F., Dogan, A., Khodos, I., de Stanchina, E., Casano, J., Kayembe, C., Tam, W., Betel, D., Foa', R., Cerchietti, L., Rabadan, R., Horwitz, S., Weinstock, D. M., and Inghirami, G.
- Subjects
0301 basic medicine ,Cancer Research ,Ruxolitinib ,precision medicine ,PDGFRA ,Biology ,lcsh:RC254-282 ,Article ,Deep sequencing ,drug discovery ,03 medical and health sciences ,0302 clinical medicine ,hemic and lymphatic diseases ,medicine ,JAK/STAT pathway ,pre-clinical model ,Anaplastic large-cell lymphoma ,Exome sequencing ,PDGFB ,Drug discovery ,patient-derived tumor xenograft ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,medicine.disease ,Lymphoma ,030104 developmental biology ,Oncology ,030220 oncology & carcinogenesis ,Cancer research ,medicine.drug - Abstract
Breast implant-associated lymphoma (BIA-ALCL) has recently been recognized as an independent peripheral T-cell lymphoma (PTCL) entity. In this study, we generated the first BIA-ALCL patient-derived tumor xenograft (PDTX) model (IL89) and a matching continuous cell line (IL89_CL#3488) to discover potential vulnerabilities and druggable targets. We characterized IL89 and IL89_CL#3488, both phenotypically and genotypically, and demonstrated that they closely resemble the matching human primary lymphoma. The tumor content underwent significant enrichment along passages, as confirmed by the increased variant allele frequency (VAF) of mutations. Known aberrations (JAK1 and KMT2C) were identified, together with novel hits, including PDGFB, PDGFRA, and SETBP1. A deep sequencing approach allowed the detection of mutations below the Whole Exome Sequencing (WES) sensitivity threshold, including JAK1G1097D, in the primary sample. RNA sequencing confirmed the expression of a signature of differentially expressed genes in BIA-ALCL. Next, we tested IL89&rsquo, s sensitivity to the JAK inhibitor ruxolitinib and observed a potent anti-tumor effect, both in vitro and in vivo. We also implemented a high-throughput drug screening approach to identify compounds associated with increased responses in the presence of ruxolitinib. In conclusion, these new IL89 BIA-ALCL models closely recapitulate the primary correspondent lymphoma and represent an informative platform for dissecting the molecular features of BIA-ALCL and performing pre-clinical drug discovery studies, fostering the development of new precision medicine approaches.
- Published
- 2020
- Full Text
- View/download PDF
11. Deficiency of metabolic regulator PKM2 activates the pentose phosphate pathway and generates TCF1 + progenitor CD8 + T cells to improve immunotherapy.
- Author
-
Markowitz GJ, Ban Y, Tavarez DA, Yoffe L, Podaza E, He Y, Martin MT, Crowley MJP, Sandoval TA, Gao D, Martin ML, Elemento O, Cubillos-Ruiz JR, McGraw TE, Altorki NK, and Mittal V
- Subjects
- Animals, Mice, Humans, Glycolysis, Membrane Proteins metabolism, Membrane Proteins genetics, Mice, Knockout, Thyroid Hormones metabolism, Programmed Cell Death 1 Receptor metabolism, Immune Checkpoint Inhibitors pharmacology, Mice, Inbred C57BL, Neoplasms immunology, Neoplasms therapy, Neoplasms metabolism, Pyruvate Kinase, Pentose Phosphate Pathway, CD8-Positive T-Lymphocytes immunology, CD8-Positive T-Lymphocytes metabolism, Hepatocyte Nuclear Factor 1-alpha metabolism, Thyroid Hormone-Binding Proteins, Immunotherapy methods
- Abstract
TCF1
high progenitor CD8+ T cells mediate the efficacy of immunotherapy; however, the mechanisms that govern their generation and maintenance are poorly understood. Here, we show that targeting glycolysis through deletion of pyruvate kinase muscle 2 (PKM2) results in elevated pentose phosphate pathway (PPP) activity, leading to enrichment of a TCF1high progenitor-exhausted-like phenotype and increased responsiveness to PD-1 blockade in vivo. PKM2KO CD8+ T cells showed reduced glycolytic flux, accumulation of glycolytic intermediates and PPP metabolites and increased PPP cycling as determined by 1,2-13 C glucose carbon tracing. Small molecule agonism of the PPP without acute glycolytic impairment skewed CD8+ T cells toward a TCF1high population, generated a unique transcriptional landscape and adoptive transfer of agonist-treated CD8+ T cells enhanced tumor control in mice in combination with PD-1 blockade and promoted tumor killing in patient-derived tumor organoids. Our study demonstrates a new metabolic reprogramming that contributes to a progenitor-like T cell state promoting immunotherapy efficacy., (© 2024. The Author(s), under exclusive licence to Springer Nature America, Inc.)- Published
- 2024
- Full Text
- View/download PDF
12. Deficiency of metabolic regulator PKM2 activates the pentose phosphate pathway and generates TCF1+ progenitor CD8+ T cells to improve checkpoint blockade.
- Author
-
Markowitz GJ, Ban Y, Tavarez DA, Yoffe L, Podaza E, He Y, Martin MT, Crowley MJP, Sandoval TA, Gao D, Martin ML, Elemento O, Cubillos-Ruiz JR, McGraw TE, Altorki NK, and Mittal V
- Abstract
TCF1
high progenitor CD8+ T cells mediate the efficacy of PD-1 blockade, however the mechanisms that govern their generation and maintenance are poorly understood. Here, we show that targeting glycolysis through deletion of pyruvate kinase muscle 2 (PKM2) results in elevated pentose phosphate pathway (PPP) activity, leading to enrichment of a TCF1high central memory-like phenotype and increased responsiveness to PD-1 blockade in vivo . PKM2KO CD8+ T cells showed reduced glycolytic flux, accumulation of glycolytic intermediates and PPP metabolites, and increased PPP cycling as determined by 1,213 C glucose carbon tracing. Small molecule agonism of the PPP without acute glycolytic impairment skewed CD8+ T cells towards a TCF1high population, generated a unique transcriptional landscape, enhanced tumor control in mice in combination with PD-1 blockade, and promoted tumor killing in patient-derived tumor organoids. Our study demonstrates a new metabolic reprogramming that contributes to a progenitor-like T cell state amenable to checkpoint blockade.- Published
- 2023
- Full Text
- View/download PDF
13. Endothelial cell-leukemia interactions remodel drug responses, uncovering T-ALL vulnerabilities.
- Author
-
Cappelli LV, Fiore D, Phillip JM, Yoffe L, Di Giacomo F, Chiu W, Hu Y, Kayembe C, Ginsberg M, Consolino L, Barcia Duran JG, Zamponi N, Melnick AM, Boccalatte F, Tam W, Elemento O, Chiaretti S, Guarini A, Foà R, Cerchietti L, Rafii S, and Inghirami G
- Subjects
- Humans, Cell Communication, Coculture Techniques, Tumor Microenvironment, Endothelial Cells metabolism, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma drug therapy, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma metabolism
- Abstract
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive and often incurable disease. To uncover therapeutic vulnerabilities, we first developed T-ALL patient-derived tumor xenografts (PDXs) and exposed PDX cells to a library of 433 clinical-stage compounds in vitro. We identified 39 broadly active drugs with antileukemia activity. Because endothelial cells (ECs) can alter drug responses in T-ALL, we developed an EC/T-ALL coculture system. We found that ECs provide protumorigenic signals and mitigate drug responses in T-ALL PDXs. Whereas ECs broadly rescued several compounds in most models, for some drugs the rescue was restricted to individual PDXs, suggesting unique crosstalk interactions and/or intrinsic tumor features. Mechanistically, cocultured T-ALL cells and ECs underwent bidirectional transcriptomic changes at the single-cell level, highlighting distinct "education signatures." These changes were linked to bidirectional regulation of multiple pathways in T-ALL cells as well as in ECs. Remarkably, in vitro EC-educated T-ALL cells transcriptionally mirrored ex vivo splenic T-ALL at single-cell resolution. Last, 5 effective drugs from the 2 drug screenings were tested in vivo and shown to effectively delay tumor growth and dissemination thus prolonging overall survival. In sum, we developed a T-ALL/EC platform that elucidated leukemia-microenvironment interactions and identified effective compounds and therapeutic vulnerabilities., (© 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
14. Gender Gap in Neurology Research Authorship (1946-2020).
- Author
-
Nguyen AX, Yoffe L, Li A, Trinh XV, Kurian J, Moss HE, and Wu AY
- Abstract
Gender disparity in the field of neurology impedes scientific advancements and innovations. In 2018, 45.0% of neurology and neurological subspecialty residents were women. Despite a notable rise in the proportion of women neurologists over the past decades, inequalities regarding publication proportions between men and women persist in the field. This cohort study examines authorship trends in articles published in 155 international neurology journals, identified as those listed in the annual Journal Citation Reports' "Clinical Neurology" section. Authors' names, authorship positions and countries of affiliation were extracted from PubMed for indexed articles published from 1946 to 2020. Gender-API (a validated and highly accurate application program interface) assigned binary genders to authors. Author gender proportions were compared across subspecialties, authorship position and years. In 303,385 unique articles, 1,663,036 total authors were identified of which 34.1% were women. Neuroradiology demonstrated the lowest proportion of women authors (21.3%), while neurogenetics displayed the highest (44.5%). In articles with multiple authors, both men and women last authors were more likely to publish with a male first author, though this was significantly more pronounced for men last authors (1.86 vs. 1.08; p < 0.001). From 2002 to 2020, women remained in the minority of last (24.6%), first (36.2%), and middle author positions (35.8%). The authorship gender distribution in neurological journals neither reflects the gender proportion of neurologists in the field overall nor in any subspecialty examined. We also find a tendency for senior and junior authors of the same gender to publish together which perpetuates authorship inequity. Further work is needed to identify underlying causes so that interventions might be developed to improve authorship diversity., Competing Interests: HM reports financial disclosures from Verily, 2020 therapeutics, Verana Health and Legal firms for consulting, and from Ology Education, American Academy of Neurology, and Vindico CME for speaking and teaching arrangements. Additionally, she reports grants from National Institutes of Health, Myelin Repair Foundation, North American Neuro-Ophthalmology Society, and Stanford. She served on a scientific advisory board for Genentech. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Nguyen, Yoffe, Li, Trinh, Kurian, Moss and Wu.)
- Published
- 2021
- Full Text
- View/download PDF
15. Assessing the involvement of the placental microbiome and virome in preeclampsia using non coding RNA sequencing.
- Author
-
Yoffe L, Kuperman AA, Isakov O, Haguel D, Polsky AL, Farberov L, Pillar N, Gurevich V, Haviv I, and Shomron N
- Subjects
- Adult, Bacteria classification, Bacteria isolation & purification, Correlation of Data, Female, Humans, Outcome Assessment, Health Care, Placenta pathology, Pregnancy, RNA, Untranslated analysis, RNA, Untranslated isolation & purification, Reproducibility of Results, Specimen Handling methods, Microbiota genetics, Placenta microbiology, Pre-Eclampsia blood, Pre-Eclampsia diagnosis, Pre-Eclampsia microbiology, RNA, Bacterial analysis, RNA, Bacterial isolation & purification, RNA, Viral analysis, RNA, Viral isolation & purification, Sequence Analysis, RNA methods, Sequence Analysis, RNA statistics & numerical data
- Abstract
Objectives: Preeclampsia is a dangerous pregnancy complication. The source of preeclampsia is unknown, though the placenta is believed to have a central role in its pathogenesis. An association between maternal infection and preeclampsia has been demonstrated, yet the involvement of the placental microbiome in the etiology of preeclampsia has not been determined. In this study, we examined whether preeclampsia is associated with an imbalanced microorganism composition in the placenta., Methods: To this end, we developed a novel method for the identification of bacteria/viruses based on sequencing of small non-coding RNA, which increases the microorganism-to-host ratio, this being a major challenge in microbiome methods. We validated the method on various infected tissues and demonstrated its efficiency in detecting microorganisms in samples with extremely low bacterial/viral biomass. We then applied the method to placenta specimens from preeclamptic and healthy pregnancies. Since the placenta is a remarkably large and heterogeneous organ, we explored the bacterial and viral RNA at each of 15 distinct locations., Results: Bacterial RNA was detected at all locations and was consistent with previous studies of the placental microbiome, though without significant differences between the preeclampsia and control groups. Nevertheless, the bacterial RNA composition differed significantly between various areas of the placenta. Viral RNA was detected in extremely low quantities, below the threshold of significance, thus viral abundance could not be determined., Conclusions: Our results suggest that the bacterial and viral abundance in the placenta may have only limited involvement in the pathogenesis of preeclampsia. The evidence of a heterogenic bacterial RNA composition in the various placental locations warrants further investigation to capture the true nature of the placental microbiome., (© 2021 Walter de Gruyter GmbH, Berlin/Boston.)
- Published
- 2021
- Full Text
- View/download PDF
16. A Novel JAK1 Mutant Breast Implant-Associated Anaplastic Large Cell Lymphoma Patient-Derived Xenograft Fostering Pre-Clinical Discoveries.
- Author
-
Fiore D, Cappelli LV, Zumbo P, Phillips JM, Liu Z, Cheng S, Yoffe L, Ghione P, Di Maggio F, Dogan A, Khodos I, de Stanchina E, Casano J, Kayembe C, Tam W, Betel D, Foa' R, Cerchietti L, Rabadan R, Horwitz S, Weinstock DM, and Inghirami G
- Abstract
Breast implant-associated lymphoma (BIA-ALCL) has recently been recognized as an independent peripheral T-cell lymphoma (PTCL) entity. In this study, we generated the first BIA-ALCL patient-derived tumor xenograft (PDTX) model (IL89) and a matching continuous cell line (IL89_CL#3488) to discover potential vulnerabilities and druggable targets. We characterized IL89 and IL89_CL#3488, both phenotypically and genotypically, and demonstrated that they closely resemble the matching human primary lymphoma. The tumor content underwent significant enrichment along passages, as confirmed by the increased variant allele frequency (VAF) of mutations. Known aberrations (JAK1 and KMT2C) were identified, together with novel hits, including PDGFB, PDGFRA, and SETBP1. A deep sequencing approach allowed the detection of mutations below the Whole Exome Sequencing (WES) sensitivity threshold, including JAK1G1097D, in the primary sample. RNA sequencing confirmed the expression of a signature of differentially expressed genes in BIA-ALCL. Next, we tested IL89's sensitivity to the JAK inhibitor ruxolitinib and observed a potent anti-tumor effect, both in vitro and in vivo. We also implemented a high-throughput drug screening approach to identify compounds associated with increased responses in the presence of ruxolitinib. In conclusion, these new IL89 BIA-ALCL models closely recapitulate the primary correspondent lymphoma and represent an informative platform for dissecting the molecular features of BIA-ALCL and performing pre-clinical drug discovery studies, fostering the development of new precision medicine approaches.
- Published
- 2020
- Full Text
- View/download PDF
17. Early diagnosis of gestational diabetes mellitus using circulating microRNAs.
- Author
-
Yoffe L, Polsky A, Gilam A, Raff C, Mecacci F, Ognibene A, Crispi F, Gratacós E, Kanety H, Mazaki-Tovi S, Shomron N, and Hod M
- Subjects
- Adipose Tissue chemistry, Adult, Case-Control Studies, Early Diagnosis, Female, Humans, Machine Learning, MicroRNAs blood, Placenta chemistry, Predictive Value of Tests, Pregnancy, Pregnancy Trimester, First, Reproducibility of Results, Circulating MicroRNA blood, Diabetes, Gestational blood, Diabetes, Gestational diagnosis
- Abstract
Design: Gestational diabetes mellitus (GDM) is one of the most common pregnancy complications and its prevalence is constantly rising worldwide. Diagnosis is commonly in the late second or early third trimester of pregnancy, though the development of GDM starts early; hence, first-trimester diagnosis is feasible., Objective: Our objective was to identify microRNAs that best distinguish GDM samples from those of healthy pregnant women and to evaluate the predictive value of microRNAs for GDM detection in the first trimester., Methods: We investigated the abundance of circulating microRNAs in the plasma of pregnant women in their first trimester. Two populations were included in the study to enable population-specific as well as cross-population inspection of expression profiles. Each microRNA was tested for differential expression in GDM vs control samples, and their efficiency for GDM detection was evaluated using machine-learning models., Results: Two upregulated microRNAs (miR-223 and miR-23a) were identified in GDM vs the control set, and validated on a new cohort of women. Using both microRNAs in a logistic-regression model, we achieved an AUC value of 0.91. We further demonstrated the overall predictive value of microRNAs using several types of multivariable machine-learning models that included the entire set of expressed microRNAs. All models achieved high accuracy when applied on the dataset (mean AUC = 0.77). The significance of the classification results was established via permutation tests., Conclusions: Our findings suggest that circulating microRNAs are potential biomarkers for GDM in the first trimester. This warrants further examination and lays the foundation for producing a novel early non-invasive diagnostic tool for GDM.
- Published
- 2019
- Full Text
- View/download PDF
18. Characterization of MicroRNA and Gene Expression Profiles Following Ricin Intoxication.
- Author
-
Pillar N, Haguel D, Grad M, Shapira G, Yoffe L, and Shomron N
- Subjects
- Animals, Leukocytes, Mononuclear metabolism, Mice, MicroRNAs genetics, Ricin toxicity, Transcriptome drug effects
- Abstract
Ricin, derived from the castor bean plant, is a highly potent toxin, classified as a potential bioterror agent. Current methods for early detection of ricin poisoning are limited in selectivity. MicroRNAs (miRNAs), which are naturally occurring, negative gene expression regulators, are known for their tissue specific pattern of expression and their stability in tissues and blood. While various approaches for ricin detection have been investigated, miRNAs remain underexplored. We evaluated the effect of pulmonary exposure to ricin on miRNA expression profiles in mouse lungs and peripheral blood mononuclear cells (PBMCs). Significant changes in lung tissue miRNA expression levels were detected following ricin intoxication, specifically regarding miRNAs known to be involved in innate immunity pathways. Transcriptome analysis of the same lung tissues revealed activation of several immune regulation pathways and immune cell recruitment. Our work contributes to the understanding of the role of miRNAs and gene expression in ricin intoxication.
- Published
- 2019
- Full Text
- View/download PDF
19. Early Detection of Preeclampsia Using Circulating Small non-coding RNA.
- Author
-
Yoffe L, Gilam A, Yaron O, Polsky A, Farberov L, Syngelaki A, Nicolaides K, Hod M, and Shomron N
- Subjects
- Adult, Biomarkers blood, Case-Control Studies, Early Diagnosis, Female, Gestational Age, Humans, Infant, Newborn, Male, Pregnancy, Pregnancy Outcome, Pregnancy Trimester, First blood, Pregnancy Trimester, Second blood, Prospective Studies, Risk Factors, Pre-Eclampsia blood, Pre-Eclampsia diagnosis, RNA, Small Untranslated blood
- Abstract
Preeclampsia is one of the most dangerous pregnancy complications, and the leading cause of maternal and perinatal mortality and morbidity. Although the clinical symptoms appear late, its origin is early, and hence detection is feasible already at the first trimester. In the current study, we investigated the abundance of circulating small non-coding RNAs in the plasma of pregnant women in their first trimester, seeking transcripts that best separate the preeclampsia samples from those of healthy pregnant women. To this end, we performed small non-coding RNAs sequencing of 75 preeclampsia and control samples, and identified 25 transcripts that were differentially expressed between preeclampsia and the control groups. Furthermore, we utilized those transcripts and created a pipeline for a supervised classification of preeclampsia. Our pipeline generates a logistic regression model using a 5-fold cross validation on numerous random partitions into training and blind test sets. Using this classification procedure, we achieved an average AUC value of 0.86. These findings suggest the predictive value of circulating small non-coding RNA in the first trimester, warranting further examination, and lay the foundation for producing a novel early non-invasive diagnostic tool for preeclampsia, which could reduce the life-threatening risk for both the mother and fetus.
- Published
- 2018
- Full Text
- View/download PDF
20. Deep sequencing analysis of viral infection and evolution allows rapid and detailed characterization of viral mutant spectrum.
- Author
-
Isakov O, Bordería AV, Golan D, Hamenahem A, Celniker G, Yoffe L, Blanc H, Vignuzzi M, and Shomron N
- Subjects
- Antiviral Agents therapeutic use, Genome, Viral, Humans, Population Dynamics, RNA Viruses genetics, Virus Diseases drug therapy, Virus Diseases virology, Viruses genetics, Biological Evolution, Genetic Variation genetics, High-Throughput Nucleotide Sequencing methods, Mutation genetics, Virus Diseases genetics, Viruses classification
- Abstract
Motivation: The study of RNA virus populations is a challenging task. Each population of RNA virus is composed of a collection of different, yet related genomes often referred to as mutant spectra or quasispecies. Virologists using deep sequencing technologies face major obstacles when studying virus population dynamics, both experimentally and in natural settings due to the relatively high error rates of these technologies and the lack of high performance pipelines. In order to overcome these hurdles we developed a computational pipeline, termed ViVan (Viral Variance Analysis). ViVan is a complete pipeline facilitating the identification, characterization and comparison of sequence variance in deep sequenced virus populations., Results: Applying ViVan on deep sequenced data obtained from samples that were previously characterized by more classical approaches, we uncovered novel and potentially crucial aspects of virus populations. With our experimental work, we illustrate how ViVan can be used for studies ranging from the more practical, detection of resistant mutations and effects of antiviral treatments, to the more theoretical temporal characterization of the population in evolutionary studies., Availability and Implementation: Freely available on the web at http://www.vivanbioinfo.org, Contact: : nshomron@post.tau.ac.il, Supplementary Information: Supplementary data are available at Bioinformatics online., (© The Author 2015. Published by Oxford University Press.)
- Published
- 2015
- Full Text
- View/download PDF
21. The possible involvement of microRNAs in preeclampsia and gestational diabetes mellitus.
- Author
-
Pillar N, Yoffe L, Hod M, and Shomron N
- Subjects
- Diabetes, Gestational diagnosis, Early Diagnosis, Female, Genetic Markers, Humans, Pre-Eclampsia diagnosis, Pregnancy, Diabetes, Gestational genetics, MicroRNAs metabolism, Pre-Eclampsia genetics
- Abstract
Great obstetrical syndromes is a collective name for several complications of pregnancy that affect >15% of pregnancies. They may confer adverse pregnancy outcomes and maternal and fetal morbidity, and require close medical monitoring and treatment. The etiology, pathogenesis, and outcome of these syndromes are obscure in the majority of cases. All appear during mid-to-late pregnancy with no reliable biomarkers for early detection and possibly prevention at present. This article focuses on the quest for early reliable markers for preeclampsia and gestational diabetes mellitus (GDM) development, mainly on the involvement of microRNA in the pathogenesis and its possible role as an early biomarker for disease development., (Copyright © 2014 Elsevier Ltd. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
22. Post-hematopoietic stem cell transplantion immune-mediated cytopenias.
- Author
-
Tsirigotis PD, Resnick IB, Or R, Elad S, Zilberman I, Yoffe L, Levovic A, Miron S, Gesundheit B, Slavin S, and Shapira MY
- Subjects
- Adult, Aged, Chimerism, Cyclosporine therapeutic use, Female, Graft vs Host Disease diagnosis, Graft vs Host Disease pathology, Graft vs Host Disease physiopathology, Graft vs Host Disease therapy, Hematopoietic Stem Cell Mobilization, Histocompatibility, Humans, Immunoglobulins, Intravenous therapeutic use, Male, Middle Aged, Myelodysplastic Syndromes, Neutropenia, Red-Cell Aplasia, Pure, Remission Induction, Thrombocytopenia, Bone Marrow pathology, Graft vs Host Disease etiology, Hematopoietic Stem Cell Transplantation, Leukemia, Myeloid, Acute therapy, Lymphoma, Non-Hodgkin therapy, Postoperative Complications, Transplantation Conditioning
- Abstract
Immune-mediated cytopenias after allogeneic stem cell transplantation can be categorized as either alloimmune when host or donor immunity reacts against donor or host elements, respectively, or autoimmune when donor immunity reacts against donor hematopoietic tissue, owing to poorly understood mechanisms that result in severe impairment of central and peripheral tolerance. Immune cytopenias are manifested as monolineage or more rarely as bilineage cytopenias, and are usually mediated through humoral immune mechanisms. On the contrary, immune-mediated pancytopenia is a rare event with only few cases reported in the literature. The exact pathogenesis of immune pancytopenia is not well known although it is possible that cellular immunity may play a significant role. The importance of these syndromes lies in the fact that they can cause severe morbidity and mortality. Differential diagnosis from other causes of post-transplant pancytopenia is of extreme value because these disorders can respond to various treatment modalities.
- Published
- 2009
- Full Text
- View/download PDF
23. Allogeneic stem cell transplantation for severe acquired aplastic anaemia using a fludarabine-based preparative regimen.
- Author
-
Resnick IB, Aker M, Shapira MY, Tsirigotis PD, Bitan M, Abdul-Hai A, Samuel S, Ackerstein A, Gesundheit B, Zilberman I, Miron S, Yoffe L, Lvovich A, Slavin S, and Or R
- Subjects
- Adolescent, Adult, Antilymphocyte Serum therapeutic use, Child, Cyclophosphamide therapeutic use, Female, Graft vs Host Disease prevention & control, Humans, Immunosuppressive Agents adverse effects, Male, Middle Aged, Mucositis chemically induced, Opportunistic Infections etiology, Pilot Projects, Quality of Life, Transplantation Chimera, Transplantation Conditioning methods, Treatment Outcome, Vidarabine therapeutic use, Anemia, Aplastic therapy, Hematopoietic Stem Cell Transplantation methods, Immunosuppressive Agents therapeutic use, Vidarabine analogs & derivatives
- Abstract
We reviewed our experience in the treatment of 13 patients with severe acquired aplastic anaemia, using a newly developed non-myeloablative regimen consisting of fludarabine (total dose 180 mg/m2), cyclophosphamide (total dose 120 mg/kg), and antithymocyte globulin (total dose 40 mg/kg). All except one patient received multiple transfusions and had failed prior immunosuppressive treatment. Twelve out of 13 patients achieved sustained engraftment. One patient was not evaluable for engraftment because of early death on day +10. None of the patients developed graft failure. Mucositis of mild-to-moderate severity was the only observed regimen-related toxicity. The cumulative incidence of acute graft-versus-host disease (GvHD) grade II-IV and III-IV was 8.3% and 0%, respectively. With a median follow-up period of 45 months, the 5-year overall survival probability was 84%. Eight out of 11 surviving patients have been followed for more than 1 year and only one developed limited chronic GvHD. All patients enjoy a normal life style, with a Karnofsky score of 100%, and all except three, followed for 3, 5 and 6 months respectively, are free of any immunosuppressive medication. The results of this study look promising, while prospective clinical trials may be required to confirm the benefits of this regimen as an alternative to existing protocols.
- Published
- 2006
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.